What treatment would you provide for a patient with bilateral synchronous locally advanced cT4dN0 TNBC and cT1b ER+ HER2+ breast cancer?

Yes, the TNBC seems to be locally advanced and being T4d, would qualify for the KEYNOTE-522 regimen. The HER-2 positive cancer is small and clinically lymph node negative, so upfront surgery followed by adjuvant anti HER-2 therapy based on APT trial would be reasonable. But since the patient would h...

The incidence of synchronous bilateral breast cancer is 1.0% to 2.6%, while the risk of developing metachronous contralateral carcinoma can be 0.9% per year, with a cumulative risk of 12% at 15 years. Lobular histology, family history, young age at diagnosis, and BRCA mutations have been associated ...